The inhibition of caspase-8 or caspase-10 (as well as disabling caspase-8) significantly reduces the efficacy of treatment, suggesting that this downstream pathway may play an important role in the response of melanoma cells to combination therapy [45]. Here, CASP10 is linked to melanoma.